Skip to main content
Log in

Uso del metirapone nel trattamento della sindrome di Cushing

  • Pratica Clinica in Endocrinologia
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. Nieman LK, Biller BM, Findling JW et al. (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Verhelst JA, Trainer PJ, Howlett TA et al. (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 35:169–178

    Article  CAS  Google Scholar 

  3. Daniel E, Aylwin S, Mustafa O et al. (2015) Effectiveness of metyrapone in treating Cushing’s syndrome. A retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 100:4146–4154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marco Boscaro.

Ethics declarations

Conflitto di interesse

Gli autori Nora M Albiger, Carla Scaroni, e Marco Boscaro dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albiger, N.M., Scaroni, C. & Boscaro, M. Uso del metirapone nel trattamento della sindrome di Cushing. L'Endocrinologo 18, 182–183 (2017). https://doi.org/10.1007/s40619-017-0339-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-017-0339-6

Navigation